Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2009
10/29/2009US20090269409 Pharmaceutical compositions comprising eszopiclone
10/29/2009US20090269407 Poly-alpha(1-4)glucopyranose-based matrices with hydrazide crosslinking
10/29/2009US20090269404 Crosslinked Gelatin Gel, Multilayered Structure, Carrier for Bioactive Factor, Preparation for Release of Bioactive Factor, and Their Production Methods
10/29/2009US20090269403 Oral contraceptive dosage forms and methods of making such dosage forms
10/29/2009US20090269402 Modified release composition of at least one form of venlafaxine
10/29/2009US20090269400 Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin
10/29/2009US20090269399 Phosphate-binding magnesium salts and uses thereof
10/29/2009US20090269396 Dual action, inhaled formulations providing both an immediate and sustained release profile
10/29/2009US20090269395 Use of protoberberines as an active substance regulating the pilosebaceous unit
10/29/2009US20090269394 Methods and compositions for treating onchomycosis
10/29/2009US20090269390 Medical devices, polymers, compositions, and methods for delivering a haloacetate
10/29/2009US20090269388 Allograft bone composition having a gelatin binder
10/29/2009US20090269385 Composite implants for promoting bone regeneration and augmentation and methods for their preparation and use
10/29/2009US20090269369 Ophthalmic Composition Comprising Xanthan Gum and Glucose
10/29/2009US20090269365 Immunogenic vaccinia peptides and methods of using same
10/29/2009US20090269363 Method for screening peptides for use in immunotherapy
10/29/2009US20090269361 Constructs for delivery of therapeutic agents to neuronal cells
10/29/2009US20090269360 Therapy
10/29/2009US20090269356 Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
10/29/2009US20090269354 Quinazoline derivatives and methods of treatment
10/29/2009US20090269352 Antitumor agent comprising sulfonamide-containing heterocyclic compound combined with an angiogenesis inhibitor
10/29/2009US20090269350 drug screening; used to identify compounds that act as agonists and antagonists and modulate the expression of the novel PGP synthase
10/29/2009US20090269337 Compositions and methods for treating diabetes
10/29/2009US20090269333 Replikin peptides in rapid replication of glioma cells and in influenza epidemics
10/29/2009US20090269331 Caspase-8 and inflammation, infection and wound healing
10/29/2009US20090269325 using non-anticoagulant sulfated polysaccharides (NASPs) e.g. pentosan polysulfate or heparins as procoagulants for treating bleeding disorder selected from a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder
10/29/2009US20090269320 Variants of pigment epithelium derived factor and uses thereof
10/29/2009US20090269305 Novel macrocyclic inhibitors of hepatitis c virus replication
10/29/2009US20090269303 Method for treating or preventing conditions by elevation of the adenosine level in an individual
10/29/2009US20090269301 Novel Inhibitors of Glutaminyl Cyclase
10/29/2009US20090269298 Agent for the prevention and treatment of sexually transmitted diseases-i
10/29/2009US20090269281 Calcium/Calmodulin-Dependent Protein Kinase Kinase as a Control Point for Cardiac Hypertrophy
10/29/2009DE202008008059U1 Zusammensetzung zur Prophylaxe und Therapie der Arthrose Composition for the prophylaxis and treatment of osteoarthritis
10/29/2009DE102008021699A1 New pyrrolopyrimidine compounds are epidermal growth factor receptor tyrosine kinase inhibitors useful for preventing or treating proliferative or inflammatory disease, where the disease is e.g. cancer, asthma, allergy and psoriasis
10/29/2009DE102008020797A1 Skin cream useful for e.g. treatment and/or prophylaxis of dry skin and/or skin damage in diabetic foot, comprises saccharide e.g. mannobiose, polysaccharide e.g. dextran, multivalent alcohol e.g. glycerol, urea, polycation and carrier
10/29/2009DE102008020633A1 Nukleosiddi- und Nukleosidtriphosphat-Prodrugs Nukleosiddi- and nucleoside prodrugs
10/29/2009DE102008020113A1 Substituierte Dihydropyrazolone und ihre Verwendung Substituted dihydropyrazolones and their use
10/29/2009DE102008020053A1 Feste pharmazeutische Zubereitung enthaltend A solid pharmaceutical preparation containing 1-[(4-chloro-phenyl)-amid]-2-{[4-(3-oxo-morpholin-4-yl)-phenyl]-amid}-4-hydroxy-pyrrolidin-1,2-dicarbonsäure
10/29/2009DE102007049630A1 New amide compounds used for therapy and/or prophylaxis of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy
10/29/2009CA2758424A1 Compounds, compositions and methods for making the same
10/29/2009CA2725578A1 Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen
10/29/2009CA2723222A1 Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
10/29/2009CA2723216A1 Iminopyridine derivatives and use thereof
10/29/2009CA2723185A1 Inhibitors of protein kinases
10/29/2009CA2722660A1 Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors
10/29/2009CA2722589A1 Improved tlr3 agonist compositions
10/29/2009CA2722529A1 Substituted gamma lactams as therapeutic agents
10/29/2009CA2722456A1 Substituted arylcyclopentenes as prostaglandin ep2 agonists
10/29/2009CA2722454A1 Substituted gamma lactams as therapeutic agents
10/29/2009CA2722445A1 Nanoemulsions for treating fungal, yeast and mold infections
10/29/2009CA2722404A1 Methods of treating fungal infections
10/29/2009CA2722403A1 Substituted arylcyclopentenes as therapeutic agents
10/29/2009CA2722393A1 Liquid formulation for deferiprone with palatable taste
10/29/2009CA2722371A1 Use of epothelone d in treating tau-associated diseases including alzheimer's disease
10/29/2009CA2722365A1 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
10/29/2009CA2722345A1 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
10/29/2009CA2722340A1 Small-molecule inhibitors of the androgen receptor
10/29/2009CA2722325A1 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
10/29/2009CA2722312A1 Thiophene derivatives useful as ocular hypotensive agents
10/29/2009CA2722306A1 Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interferon-alpha-2a/2b and ribavirin
10/29/2009CA2722288A1 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
10/29/2009CA2722258A1 N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway
10/29/2009CA2722256A1 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors
10/29/2009CA2722255A1 Inhibitors of ikk-.beta. serine-threonine protein kinase
10/29/2009CA2722248A1 Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
10/29/2009CA2722246A1 Nalmefene prodrugs
10/29/2009CA2722243A1 Nalmefene di-ester prodrugs
10/29/2009CA2722211A1 Compositions for the treatment of vaginal infections with chronic inflammation
10/29/2009CA2722209A1 Compositions for the treatment and prevention of infections of the oral cavity
10/29/2009CA2722183A1 Nanostructures suitable for sequestering cholesterol and other molecules
10/29/2009CA2722177A1 1'-substituted carba-nucleoside analogs for antiviral treatment
10/29/2009CA2722159A1 Substituted phenylimidazole compounds and their use as ido inhibitors
10/29/2009CA2722139A1 Carboxamide compounds for the treatment of metabolic disorders
10/29/2009CA2722112A1 Treating eosinophilic esophagitis
10/29/2009CA2722084A1 Carba-nucleoside analogs for antiviral treatment
10/29/2009CA2722075A1 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009CA2722067A1 Benzimidazole derivatives as calcium channel blockers
10/29/2009CA2722041A1 Novel five-membered ring compound
10/29/2009CA2722035A1 Quinoline or isoquinoline substituted p2x7 antagonists
10/29/2009CA2722031A1 Iminopyridine derivative and use thereof
10/29/2009CA2722028A1 5-hydroxypyrimidine-4-carboxamide compound
10/29/2009CA2722020A1 Improved raf inhibitors
10/29/2009CA2722007A1 Five-membered ring compound
10/29/2009CA2721986A1 Rehydratable polysaccharide particles and sponge
10/29/2009CA2721985A1 Thiolated chitosan gel
10/29/2009CA2721980A1 Selective high-affinity polydentate ligands and methods of making such
10/29/2009CA2721938A1 Chitosan-containing protective composition
10/29/2009CA2721937A1 Protective gel based on chitosan and oxidized polysaccharide
10/29/2009CA2721927A1 Auris formulations for treating otic diseases and conditions
10/29/2009CA2721920A1 Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components
10/29/2009CA2721919A1 Limk2 inhibitors, compositions comprising them, and methods of their use
10/29/2009CA2721910A1 Cyclobutyl sulfones as notch sparing gamma secretase inhibitors
10/29/2009CA2721908A1 (5r)-1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives having cb1-antagonistic activity
10/29/2009CA2721858A1 Pyridazinone derivatives
10/29/2009CA2721756A1 Fatty acid derivatives for oral administration endowed with high palatability
10/29/2009CA2721750A1 Carbamate and urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1
10/29/2009CA2721738A1 Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
10/29/2009CA2721576A1 Compound having npy y5 receptor antagonist activity
10/29/2009CA2721575A1 Aryl-quinolyl compounds and their use
10/29/2009CA2721542A1 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
1 ... 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 ... 7860